Figure 4.
The monoclonal antibody (mAb) 2D6 interacts with FcγRIIb on B cells and gives rise to artefactual changes in CD22 expression upon interleukin-4 (IL-4) treatment. Binding of protein-N-glycosidase F-treated, or mock-treated, mAb 2D6 to FcγRIIb-deficient and control B220+ splenocytes was examined by flow cytometry (a). (b) Purified splenic B cells were stimulated with anti-μ F(ab′)2 or lipopolysaccharide (LPS) for 48 hr, in the presence or absence of 10 ng/ml IL-4 as indicated. Binding of mAbs 2D6 and Cy34.1 was assessed by flow cytometry. Traces are representative of cells from three mice in each case.